Omeros Corporation (NASDAQ:OMER – Free Report) – Research analysts at HC Wainwright raised their Q3 2026 earnings per share (EPS) estimates for shares of Omeros in a report issued on Thursday, August 13th. HC Wainwright analyst B. Folkes now expects that the biopharmaceutical company will earn ($0.05) per share for the quarter, up from their previous forecast of ($0.22). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Omeros’ current full-year earnings is ($0.37) per share. HC Wainwright also issued estimates for Omeros’ Q4 2026 earnings at ($0.09) EPS, FY2026 earnings at ($0.37) EPS, FY2027 earnings at $0.24 EPS and FY2028 earnings at $1.63 EPS.
A number of other research firms have also recently weighed in on OMER. Wall Street Zen raised Omeros from a “hold” rating to a “buy” rating in a research report on Saturday. Weiss Ratings raised shares of Omeros from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, August 5th. Zacks Research cut shares of Omeros from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. Finally, D. Boral Capital restated a “buy” rating and set a $36.00 target price on shares of Omeros in a research note on Tuesday, April 21st. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $38.00.
Omeros Stock Down 1.0%
Shares of OMER opened at $17.19 on Monday. The business has a 50-day simple moving average of $11.18 and a two-hundred day simple moving average of $11.61. The stock has a market cap of $1.24 billion, a price-to-earnings ratio of 13.43 and a beta of 2.54. Omeros has a 52 week low of $3.94 and a 52 week high of $18.14.
Omeros (NASDAQ:OMER – Get Free Report) last released its earnings results on Thursday, August 13th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.29. The company had revenue of $28.53 million for the quarter, compared to analysts’ expectations of $12.69 million.
Insider Activity
In other news, Director Thomas J. Cable sold 7,500 shares of the business’s stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $11.61, for a total value of $87,075.00. Following the transaction, the director directly owned 35,067 shares in the company, valued at $407,127.87. The trade was a 17.62% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO David J. Borges sold 5,000 shares of the company’s stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $16.95, for a total value of $84,750.00. Following the completion of the transaction, the chief accounting officer directly owned 5,000 shares of the company’s stock, valued at approximately $84,750. This trade represents a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 10.50% of the stock is owned by insiders.
Institutional Investors Weigh In On Omeros
Institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. purchased a new position in Omeros during the second quarter valued at $57,484,000. UBS Group AG boosted its holdings in shares of Omeros by 213.5% during the 4th quarter. UBS Group AG now owns 2,222,982 shares of the biopharmaceutical company’s stock valued at $38,180,000 after purchasing an additional 1,513,893 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Omeros by 19.9% during the fourth quarter. Vanguard Group Inc. now owns 4,013,315 shares of the biopharmaceutical company’s stock valued at $68,929,000 after purchasing an additional 666,357 shares in the last quarter. Corient Private Wealth LP purchased a new position in shares of Omeros during the second quarter valued at about $6,274,000. Finally, JPMorgan Chase & Co. increased its holdings in shares of Omeros by 1,201.1% in the third quarter. JPMorgan Chase & Co. now owns 416,153 shares of the biopharmaceutical company’s stock worth $1,706,000 after purchasing an additional 384,168 shares during the last quarter. Institutional investors own 48.79% of the company’s stock.
About Omeros
Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.
Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.
Featured Articles
- Five stocks we like better than Omeros
- The AI Boom Is Turning This Cable Maker Into a Stock to Watch
- A Star Investor Just Trimmed Amazon—Here’s What It means
- Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look
- Home Depot Analysts See a Path to $375 and Beyond
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.
